High apolipoprotein M serum levels correlate with chronic obstructive pulmonary disease

[1]  M. R. Siddiqui,et al.  Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .

[2]  R. Proia,et al.  HDL-bound sphingosine 1-phosphate restrains lymphopoiesis and neuroinflammation , 2015, Nature.

[3]  E. Walters,et al.  Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease , 2014, International journal of chronic obstructive pulmonary disease.

[4]  O. Resta,et al.  Correlation between Inflammatory Markers of Atherosclerosis and Carotid Intima-Media Thickness in Obstructive Sleep Apnea , 2014, Molecules.

[5]  M. Tobin,et al.  APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema , 2013, European Respiratory Journal.

[6]  Wei Zhang,et al.  Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models. , 2013, Molecular medicine reports.

[7]  C. Christoffersen,et al.  The Apolipoprotein M–Sphingosine-1-Phosphate Axis: Biological Relevance in Lipoprotein Metabolism, Lipid Disorders and Atherosclerosis , 2013, International journal of molecular sciences.

[8]  M. Puhan,et al.  Determinants of endothelial function in patients with COPD , 2013, European Respiratory Journal.

[9]  T. Lehtimäki,et al.  Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: the Cardiovascular Risk in Young Finns study , 2012, European journal of preventive cardiology.

[10]  Adam Linder,et al.  Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes , 2012, Critical Care.

[11]  M. Kohler,et al.  Vascular dysfunction in chronic obstructive pulmonary disease: current evidence and perspectives , 2012, Expert review of respiratory medicine.

[12]  M. Ingersoll,et al.  Monocyte trafficking in acute and chronic inflammation. , 2011, Trends in immunology.

[13]  F. Liu,et al.  Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication , 2011, Lipids in Health and Disease.

[14]  A. Hoofnagle,et al.  Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. , 2011, Atherosclerosis.

[15]  B. Dahlbäck,et al.  Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M , 2011, Proceedings of the National Academy of Sciences.

[16]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[17]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[18]  A. Valipour,et al.  Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[19]  C. Lavie,et al.  The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. , 2008, Reviews in cardiovascular medicine.

[20]  B. Dahlbäck,et al.  The Signal Peptide Anchors Apolipoprotein M in Plasma Lipoproteins and Prevents Rapid Clearance of Apolipoprotein M from Plasma* , 2008, Journal of Biological Chemistry.

[21]  K. Feingold,et al.  Infection and inflammation decrease apolipoprotein M expression. , 2008, Atherosclerosis.

[22]  S. Novo,et al.  Clinical findings of Takotsubo cardiomyopathy: results from a multicenter international study , 2008, Journal of cardiovascular medicine.

[23]  B. Porse,et al.  Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice* , 2008, Journal of Biological Chemistry.

[24]  D. Mannino,et al.  Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.

[25]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[26]  E. Brilakis,et al.  Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. , 2005, The New England journal of medicine.

[27]  D. Sin,et al.  The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. , 2005, Chest.

[28]  M. N. Poy,et al.  Apolipoprotein M is required for preβ-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis , 2005, Nature Medicine.

[29]  P. Nilsson-ehle,et al.  Apolipoprotein M , 2004, Lipids in Health and Disease.

[30]  P. Nilsson-ehle,et al.  Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. , 2004, Biochemical and biophysical research communications.

[31]  P. Nilsson-ehle,et al.  Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells. , 2002, Biochemical and biophysical research communications.

[32]  A. Sharrett,et al.  Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.

[33]  A. Verin,et al.  Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. , 2001, The Journal of clinical investigation.

[34]  K. Feingold,et al.  Infection and inflammation induce LDL oxidation in vivo. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[35]  K. Feingold,et al.  Infection and inflammation-induced proatherogenic changes of lipoproteins. , 2000, The Journal of infectious diseases.

[36]  A. von Eckardstein,et al.  High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. , 1996, Atherosclerosis.

[37]  R. Krauss,et al.  The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. , 1993, The Journal of clinical endocrinology and metabolism.

[38]  R. Krauss,et al.  Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. , 1993, The American journal of medicine.

[39]  G. Bondjers,et al.  Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. , 1990, Journal of lipid research.

[40]  P. Clifton,et al.  Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. , 1985, Journal of lipid research.

[41]  Shuiping Zhao,et al.  Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation. , 2007, Medical hypotheses.